TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of NMO, as defined by 2006 criteria OR NMO seropositive spectrum disorder (Recurrent ON or longitudinally extensive transverse myelitis (LETM)). All patients must be NMO-IgG seropositive.~2. Clinical evidence of at least 2 relapses in last 6 months or 3 relapses in the last 12 months (with at least 1 relapse occurring in the preceding 6 months).~3. Age ≥18 years~4. Corrected visual acuity 20/100 or better in at least one eye. If fails item # 4 then entry allowed but only if last attack was myelitis and only attacks of myelitis are considered as outcome measurement.~5. Ambulatory (with or without walker). If fails item # 5 then entry allowed but only if last attack was ON and only attacks of ON are considered as outcome measurement.~6. Provision of written informed consent (see attached) to participate in the study.~7. N. meningitidis vaccination at least 14 days prior to receiving the first eculizumab infusion. If patient in midst of an acute relapse, then relapse will be treated with standard therapy and vaccination given only after a minimum of 4 weeks post attack onset.~Exclusion Criteria:~Candidates will be excluded from study entry if any of the following criteria are met at the time of randomization:~1. Progressive neurological deterioration unrelated to relapses of ON or myelitis.~2. Pregnant, breastfeeding, or intending to conceive during the course of the study~3. Patients will not participate in any other clinical therapeutic study or will not have participated in any other experimental treatment study within 30 days of screening~4. Patients with a history of splenectomy, because of a potential increased risk of developing meningococcal infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks. Subjects will receive therapy for a total of 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vascular and Skeletal Protective Effects of Genistein in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least one year of menopause~* No use of hormone replacement therapy~* Bone mineral density T-score at the femoral neck minor than one S.D.~Exclusion Criteria:~* Concomitant disease~* Smoke habit

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients must have evidence of persistent or progressive follicular grade, 1, 2 or 3 or marginal zone B-cell non-Hodgkin's lymphoma.~* Must have received at least two prior courses of systemic treatment including at least one treatment of rituximab (lymphoma must not have progressed during their most recent systemic chemotherapy treatment).~* Must have evidence that their lymphoma expresses CD20 antigen and have adequate renal and hepatic function.~Exclusion criteria:~* Received chemotherapy, radiation therapy, immunosuppressants or cytokine treatment within 4 weeks prior to study entry.~* Have active obstructive hydronephrosis.~* Had prior autologous hematopoietic stem cell transplant or any allogenic stem cell transplant.~* Have active infection requiring IV antibiotics.~* Have brain or leptomeningeal metastasis.~* Had previous allergic reaction to iodine, previously received radioimmunotherapy or are currently receiving approved or experimental anti-cancer drugs.~* Patients who are pregnant or breast feeding, have known HIV infection, or are Human anti-murine antibody (HAMA) positive.~* Other criteria will be evaluated at the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Participants underwent two phases of treatment: an initial DD, followed by a therapeutic dose. The one-day DD comprised a 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with 185 MBq (5.0 mCi) of I 131. After 7 to 14 days, the one-day therapeutic dose comprised a second 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with I 131 with an administered activity (MBq or mCi) determined from the dosimetry calculation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal status as defined by amenorrhea for \>12 months, OR history of bilateral salpingoophrectomy, OR if the patient has had a hysterectomy defined by menopausal symptoms for \>1 year OR age \>55~2. Documented recurrent UTIs (3 or more in the last year or 2 or more in the last 6 months)- one UTI must be documented by culture, others may be documented by urinalysis~3. Ability to provide informed consent~Exclusion Criteria:~1. Use of any investigational drug or device within thirty days of screening~2. Urologic surgery within the past 3 months of screening or plan for surgery within one year of screening~3. Diagnosis of Interstitial Cystitis/painful bladder syndrome~4. History of urinary tract infections which require the use of IV antibiotics or where only one oral antibiotic is available for treatment, or where the risk of treatment with vaginal estrogen only is deemed unacceptable by the principle investigator secondary to the severity of prior urinary tract infections~5. Known etiology of infection such as, but not limited to: kidney or bladder stones, enterovaginal/vesical fistula, fecal incontinence, intermittent catheterization, indwelling catheter, poorly controlled diabetes~6. Urothelial cancer~7. Actively treated estrogen sensitive tumor (breast or endometrial cancer)~8. Undiagnosed vaginal bleeding~9. Inability to use a vaginal ring (secondary to advanced prolapse or shortened vaginal length)~10. Any medical reason the investigator deems incompatible with treatment with vaginal estrogen~11. Prolapse requiring pessary use~Deferral Criteria~1. Undiagnosed hematuria - may enroll after malignancy is ruled out~2. Use of a progestin containing intrauterine device or use of any vaginal androgens, estrogens or progestins within 3 months of enrollment - may enroll after wash out~3. Use of drugs/supplements known to prevent UTIs (ie cranberry products, prophylactic antibiotics, methenamine hippurate) 1 month prior to enrollment - may enroll after wash out if still meets inclusion criteria.~4. History of estrogen sensitive tumor (breast or endometrial cancer) - requires approval by the subject's primary oncologist or primary care physician

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Conjugated Estrogen Vaginal Cream (Type: EXPERIMENTAL): Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly
- Estradiol Ring (Type: EXPERIMENTAL): Estradiol Ring per vagina every 3 months
- Placebo (Type: PLACEBO_COMPARATOR): Per vagina

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients after first clinical event suggestive of multiple Sclerosis (MS) (according to SmPC) and patients with Relapsing / Remitting Multiple Sclerosis (RRMS) within the first two years of diagnosis.~Exclusion Criteria:~* Contra-indications as indicated in Betaferon summary of Products Characteristics (SmPC)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be diagnosed with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF) according to the 2008 World Health Organization criteria~* Subjects with myelofibrosis requiring therapy must be classified as high risk OR intermediate risk level 2 according to the prognostic factors defined by the International Working Group~* Subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2 or 3~* Subjects who have not previously received treatment with a Janus kinase (JAK) inhibitor~Exclusion Criteria:~* Subjects with a life expectancy of less than 6 months~* Subjects with inadequate bone marrow reserve as demonstrated by specific clinical laboratory counts~* Subjects with inadequate liver or renal function~* Subjects with clinically significant bacterial, fungal, parasitic or viral infection which require therapy~* Subjects with an active malignancy over the previous 5 years except specific skin cancers.~* Subjects with severe cardiac conditions~* Subjects who have had splenic irradiation within 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): Participants received ruxolitinib orally twice a day. The starting dose was determined based on Baseline platelet count. Patients with Baseline platelet count \> 200,000/μL began a dose regimen of 20 mg twice daily. Patients with Baseline platelet count of 100,000/μL to 200,000/μL (inclusive) began a dose regimen of 15 mg twice daily. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily. Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting certain protocol requirements detailed below were given the opportunity to cross over to ruxolitinib treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of H1N1 Influenza Vaccination in Pregnant Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy pregnant women~2. Be able to show legal identity card for the sake of recruitment~3. Be able to understand and sign the informed consent~Exclusion Criteria:~1. Cases, cured cases and close contact of influenza A (H1N1) virus~2. Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc~3. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain~4. Autoimmune disease or immunodeficiency~5. Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids~6. Diabetes mellitus (type I or II), with the exception of gestational diabetes~7. History of thyroidectomy or thyroid disease that required medication within the past 12 months~8. Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years~9. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws~10. Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)~11. History of any blood products or seasonal influenza vaccine administration within 3 months before the dosing~12. Administration of any other investigational research agents within 30 days before the dosing~13. Administration of any live attenuated vaccine within 30 days before the dosing~14. Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing~15. Axillary temperature \> 37.0 centigrade at the time of dosing~16. Psychiatric condition that precludes compliance with the protocol~17. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- split-virion, non-adjuvanted H1N1 vaccine of 15 μg (Type: EXPERIMENTAL): split-virion, non-adjuvanted H1N1 vaccine of 15 μg made by Shanghai Institute of Biological Products lot number: 200909008

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal women able to comply with the protocol requirements with confirmed primary invasive breast cancer whose tumours are estrogen-and/or progesterone-receptor positive~2. Clinical stage T2 or \>T2 tumours which in the investigators' opinion would not be eligible for breast-conserving surgery. The nodal status will be evaluated by palpation and/or ultrasound.~3. Postmenopausal status defined by one of the following:~   * Women with an intact uterus AND~     * ≥ 55 years of age, OR~    * \< 55 years of age without menses for the last 5 years, OR~    * \< 55 years of age and have not had menses for at least the last 12 months (but have had menses in the last 5 years) and have postmenopausal levels of follicle-stimulating hormone.~  * Women without an intact uterus AND~     * ≥ 55 years of age, OR~    * \< 55 years of age and postmenopausal levels of follicle-stimulating hormone~  * Both ovaries removed (prior to the diagnosis of breast cancer).~4. Tumour measurable by clinical examination, mammography and ultrasound~5. Adequate bone marrow function as shown by:~   * WBC ≥ 3.5 x 10\^9/L~  * ANC ≥ 1.5 x 10\^9/L~  * Platelets ≥ LLN~  * Hb \> 10 g/dL~Exclusion Criteria:~1. Multifocal disease (cancer that starts in several different sites)~2. Patients with bilateral breast tumours.~3. Patients who are eligible for breast conserving surgery.~4. Evidence of inflammatory breast cancer or distant metastasis.~5. Simultaneous anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers, endocrine therapy (including steroids), bisphosphonate therapy and radiotherapy. NOTE: Bisphosphonate therapy for osteoporosis is NOT excluded, and can be continued. Patients who have received hormone replacement therapy will NOT be excluded if it is discontinued at least 2 weeks before starting the study.~The following additional treatments are NOT allowed during the treatment phase of the study:~* Any other anti-cancer therapy~* Hormone replacement therapy.~* Estrogen cream (including any intra-vaginal preparation).~* Steroids other than creams or inhalers.~* Megestrol acetate for the treatment of hot flushes.~* Radiation therapy.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Letrozole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fluoxetine (Prozac) on Domestic Violence

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Men and women over the age of 18 will be eligible for the study if they have:~A history of at least two episodes of physical aggression (i.e., hitting, pushing, punching, choking etc.) toward their spouse or significant other in the past year;~A history of at least one episode of physical aggression toward their spouse or significant other which occurred when the perpetrator had not used alcohol/drugs for at least a day;~A score of at least 3 on the Straus Conflict Tactics physical violence subscale;~A signed informed consent for participation in the protocol; and~Agreed to provide investigators with phone numbers of family and/or friends who will be able to provide information about the perpetrators' whereabouts in the event that the perpetrator does not come to appointments.~EXCLUSION CRITERIA:~Participants under the age of 18 will be excluded from the protocol because the generalizability of the results could potentially be compromised;~Abnormal laboratory or diagnostic tests which are judged to be clinically significant;~History of schizophrenia or bipolar disorder;~Participants judged to be a significant suicide/homicide risk;~Head trauma resulting in a period of unconsciousness lasting longer than one hour;~Documented seizure disorder (alcohol withdrawal seizures are not exclusionary);~History of a major medical problem (i.e., diabetes, cancer);~Women with a positive pregnancy test or women of childbearing age who are not willing to use some form of birth control during the study;~Participants whose spouse/significant other is pregnant;~Participants using an SSRI on a regular basis in the last three months;~Participants requiring other psychotropic medications;~Perpetrators requiring medications that inhibit CYP2D6, and could potentially interact with fluoxetine;~Individuals who are unwilling to forgo access to guns for the duration of the study;~Participants who are very controlling and are currently stalking their partner;~Participants who engage in forced sex;~Participants whose spouse/significant other feel that they are in great danger; and~Participants participating in the functional MRI paradigm will be excluded if they have ferromagnetic objects in their bodies which might be aversely affected by MRI (e.g., surgical clips; metal fragments in or near brain, eye, or blood vessels; cardiac or neurological pacemaker; cochlear or eye implant).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fire Fighter Fatigue Management Program: Operation Healthy Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* This proposal includes research involving human subjects (fire department employees).~* Active firefighters working in the study fire department will be eligible to participate in the study.~* All applicants will be considered without bias, regardless of race, ethnicity, or national origin.~Exclusion Criteria:~* Non fire department employees

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Workplace-based fatigue risk management program consisting of sleep health education and sleep disorders screening. The 32 fire department stations were paired according to the previous calendar years' workload. One station from each pair was randomly assigned to receive the intervention program. Sleep education sessions were scheduled according to station. On the education day(s) assigned to that stations, all personnel present that day were instructed to attend, and 542/601 did so.
- Control (Type: NO_INTERVENTION): Current practice. Firefighters in the Control Stations continued their normal role and were not invited to attend the sleep education and sleep disorders screening program. There was no formal contact with the control group.~As part of normal operational requirements, a small number of firefighters are reassigned to other stations each day and therefore 18/588 firefighters from control stations happened to be reassigned to an intervention station on the day of the education session and attended the session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete